← Leaderboards
John Cureton Hunter
Siteone Therapeutics, Inc.
$6,388,430
Attributed
$12,776,859
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2019–23$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,776,859 · 4
By mechanism
UG3$10,719,732 · 2
R44$1,733,394 · 1
R43$323,733 · 1
Top collaborators
- John Vincent Mulcahy3 shared
- Debra Odink2 shared
- Sheri Denet Klas1 shared
Most similar at Siteone Therapeutics, Inc.
Same institution · by research overlap
- John Vincent Mulcahy$6,301,912
- Anton Delwig$2,325,019
- Sheri Denet Klas$1,802,944
- Debra Odink$3,260,885
- George Miljanich$601,209
Others in their field
Other Emerging Leaders on “Afferent Neurons”
- Fritzie Isip Arce-McShane · University Of Chicago$8,847,210
- William Russell Renthal · Brigham And Women'S Hospital$6,105,785
- Anthony J St Leger · University Of Pittsburgh At Pittsburgh$5,632,093
- Sviatoslav Bagriantsev · Yale University$5,612,775
- Kathleen E Cullen · Jackson Laboratory$5,384,461
- Moran Amit · University Of Tx Md Anderson Can Ctr$4,827,924
Research focus
Afferent NeuronsProtein IsoformsVoltageDoseSmall Molecule InhibitorSodium ChannelDrug KineticsSafetyAdultProgramsPharmaceutical PreparationsExhibitsAcuteReportingStimulusSmall Business Innovation Research GrantSeriesRattusReflex ActionBasePropertyNonhuman PrimateMechanicsInhibitor/Antagonist
Grant awards (6)
Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$5,341,667
UG3 · FY2023 · DA · contact PI
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$1,055,826
R44 · FY2022 · HL · contact PI
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$677,568
R44 · FY2021 · HL · contact PI
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$2,440,102
UG3 · FY2020 · DA · contact PI
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$2,937,963
UG3 · FY2019 · DA · contact PI
Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough$323,733
R43 · FY2019 · HL · contact PI